AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19563707 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 0.02 mg.kg(‐1).h(‐1) combined with ketamine 0.08 mg.kg(‐1).h(‐1) for 50 h (group mk)
Number of subjects: 30
Study 19563707 — intervention group
Group type: COMPARATOR
Intervention: Morphine 0.02 mg.kg(‐1).h(‐1) (group m)
Number of subjects: 30
Study 17241184 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary enalaprilat (50 micro g)
Number of subjects: 22
Study 17241184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 15266832 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbidol (200 mg three times daily for 5 days)
Number of subjects: 232
Study 15266832 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbidol
Number of subjects: 232
Study 15266832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study 11890486 — intervention group
Group type: EXPERIMENTAL
Intervention: MDS-HC assessment
Number of subjects: 187
Study 11890486 — intervention group
Group type: COMPARATOR
Intervention: Conventional geriatric assessment (Barthel, Lawton and Brody, MMSE)
Number of subjects: 187
Study 9506732 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (2.5-10 mg/day)
Number of subjects: 20
Study 9506732 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinagolide (0.075-0.3 mg/day)
Number of subjects: 20
Study 9506732 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (0.5-1.5 mg/week)
Number of subjects: 20
Study 9506732 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 8792109 — intervention group
Group type: EXPERIMENTAL
Intervention: Thor‐Lo footwear
Number of subjects: 50
Study 2254714 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg d-1)
Number of subjects: 48
Study 2254714 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (75 mg d-1)
Number of subjects: 48
Study 2254714 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclophenac sodium (75 mg d-1)
Number of subjects: 48
Study 2254714 — intervention group
Group type: EXPERIMENTAL
Intervention: Second drug (when fever relapsed)
Number of subjects: 48
Study 6793609 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide (100 micrograms orally)
Number of subjects: 6
Study 6793609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31905041 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA) - Group 1
Number of subjects: 105
Study 31905041 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia (SA) - Group 2
Number of subjects: 105
Study 31905041 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural Anesthesia (EA) - Group 3
Number of subjects: 105
Study 31905041 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 105
Study 31146380 — intervention group
Group type: EXPERIMENTAL
Intervention: COANT (diet with vitamin E and selenium as antioxidants)
Number of subjects: 100
Study 31146380 — intervention group
Group type: EXPERIMENTAL
Intervention: OANT (diet with sunflower oil containing more vitamin E and selenium as antioxidants)
Number of subjects: 100
Study 31146380 — intervention group
Group type: EXPERIMENTAL
Intervention: OIL (diet with sunflower oil)
Number of subjects: 100
Study 31146380 — intervention group
Group type: COMPARATOR
Intervention: SM (skim milk)
Number of subjects: 100
Study 28104105 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10mg
Number of subjects: 134
Study 28104105 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160mg
Number of subjects: 134
Study 28104105 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5mg + Valsartan 80mg
Number of subjects: 134
Study 28104105 — intervention group
Group type: COMPARATOR
Intervention: Control (low-dose monotherapy)
Number of subjects: 134
Study 27091813 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual team intervention including social work evaluation, team-based electronic consultation, case management, and psychotherapy over a 12 month period.
Number of subjects: 250
Study 27091813 — intervention group
Group type: COMPARATOR
Intervention: Membership program providing health classes and other services to support chronic disease self-management.
Number of subjects: 250
Study 25301296 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (30 mg Fe daily as FeSO4-containing syrup for eight weeks starting immediately after malaria treatment)
Number of subjects: 48
Study 25301296 — intervention group
Group type: COMPARATOR
Intervention: Delayed iron supplementation (30 mg Fe daily as FeSO4-containing syrup for eight weeks starting two weeks after malaria treatment)
Number of subjects: 48
Study 22453267 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT-S
Number of subjects: 87
Study 22453267 — intervention group
Group type: COMPARATOR
Intervention: TVT-O
Number of subjects: 87
Study 21242610 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal treadmill test
Number of subjects: 88
Study 21242610 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-validation statistics
Number of subjects: 88
Study 18051006 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical grooves in the buccal and lingual walls (G2)
Number of subjects: 40
Study 18051006 — intervention group
Group type: EXPERIMENTAL
Intervention: "Pot holes" in the gingival wall (G3)
Number of subjects: 40
Study 18051006 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal grooves in the gingival wall (G4)
Number of subjects: 40
Study 18051006 — intervention group
Group type: COMPARATOR
Intervention: No retention (G1)
Number of subjects: 40
Study 16139121 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent implantation (ST) arm
Number of subjects: 450
Study 16139121 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty (BA) arm
Number of subjects: 450
Study 12010235 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionyl-l-carnitine (2 g/day for 3 months) plus verapamil (10 mg weekly for 10 weeks)
Number of subjects: 75
Study 12010235 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (40 mg/day for 3 months) plus verapamil (10 mg weekly for 10 weeks)
Number of subjects: 75
Study 12010235 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionyl-l-carnitine plus verapamil
Number of subjects: 75
Study 9390113 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.04 mg/kg dexamethasone
Number of subjects: 9
Study 9390113 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg dexamethasone
Number of subjects: 9
Study 9390113 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 9
Study 8133126 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory ST-recording
Number of subjects: 95
Study 8133126 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise test
Number of subjects: 95
Study 8133126 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk exercise test response
Number of subjects: 95
Study 8133126 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe coronary lesions
Number of subjects: 95
Study 8133126 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-depression during ST-recording
Number of subjects: 95
Study 8133126 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-depression at ambulatory monitoring
Number of subjects: 95
Study 3310020 — intervention group
Group type: EXPERIMENTAL
Intervention: nabumetone (1000 mg at bedtime)
Number of subjects: 40
Study 3310020 — intervention group
Group type: COMPARATOR
Intervention: naproxen (250 mg twice daily)
Number of subjects: 40
Study 29363990 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 14
Study 29363990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 27301220 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional education and dietary intervention for six months
Number of subjects: 90
Study 27301220 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 90
Study 25257291 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 25935 12 mg twice a day
Number of subjects: 140
Study 25257291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 22282868 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium/long-chain triglycerides and soybean oil (MCTs/LCTs)
Number of subjects: 25
Study 22282868 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure fish oil (FO)
Number of subjects: 25
Study 20660003 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour size >2 cm
Number of subjects: 351
Study 20660003 — intervention group
Group type: EXPERIMENTAL
Intervention: pT4a-category
Number of subjects: 351
Study 20660003 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour size
Number of subjects: 351
Study 20660003 — intervention group
Group type: COMPARATOR
Intervention: pT3b-tumours
Number of subjects: 351
Study 20660003 — intervention group
Group type: COMPARATOR
Intervention: Follicular thyroid carcinomas (FTC)
Number of subjects: 351
Study 18768436 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil (epi-CMF)
Number of subjects: 322
Study 18768436 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate, and fluorouracil (CMF)
Number of subjects: 322
Study 15707567 — intervention group
Group type: EXPERIMENTAL
Intervention: Simply modified no-scalpel vasectomy (SMNSV)
Number of subjects: 417
Study 15707567 — intervention group
Group type: COMPARATOR
Intervention: Standard no-scalpel vasectomy (SNSV)
Number of subjects: 417
Study 12407126 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg, amoxicillin 1 g and clarithromycin 500 mg (triple therapy)
Number of subjects: 12
Study 10630486 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (400 mg twice daily), clarithromycin (500 mg twice daily), and tinidazole (500 mg twice daily) for six days (Group A)
Number of subjects: 80
Study 10630486 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (400 mg twice daily), clarithromycin (500 mg twice daily), and tinidazole (500 mg twice daily) for seven days (Group B)
Number of subjects: 80
Study 10630486 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80
Study 7574903 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation
Number of subjects: 0
Study 7574903 — intervention group
Group type: COMPARATOR
Intervention: Control (no multivitamin supplementation)
Number of subjects: 0
Study 1670598 — intervention group
Group type: EXPERIMENTAL
Intervention: d-tubocurarine
Number of subjects: 32
Study 1670598 — intervention group
Group type: EXPERIMENTAL
Intervention: vecuronium
Number of subjects: 32
Study 1670598 — intervention group
Group type: EXPERIMENTAL
Intervention: pancuronium
Number of subjects: 32
Study 1670598 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 32
Study 1670598 — intervention group
Group type: COMPARATOR
Intervention: succinylcholine
Number of subjects: 32
Study 6340412 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin treatment for early closure of patent ductus arteriosus in 13 infants at a median age of 18 hours.
Number of subjects: 37
Study 6340412 — intervention group
Group type: COMPARATOR
Intervention: Control group of 14 infants with open ductus arteriosus who did not receive indomethacin.
Number of subjects: 37
Study 30557916 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibegron 50 mg/day
Number of subjects: 669
Study 30557916 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibegron 100 mg/day
Number of subjects: 669
Study 30557916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 669
Study 30557916 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibegron 50 mg/day and 100 mg/day
Number of subjects: 669
Study 29769827 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low-Carbohydrate High-Fat (VLCHF) diet for 4 weeks
Number of subjects: 18
Study 29769827 — intervention group
Group type: COMPARATOR
Intervention: Habitual Mixed Western-based Diet (HD)
Number of subjects: 18
Study 26386473 — intervention group
Group type: EXPERIMENTAL
Intervention: Snus
Number of subjects: 0
Study 26386473 — intervention group
Group type: COMPARATOR
Intervention: Medicinal nicotine
Number of subjects: 0
Study 24624241 — intervention group
Group type: EXPERIMENTAL
Intervention: McKenzie Protocol (MP)
Number of subjects: 84
Study 24624241 — intervention group
Group type: EXPERIMENTAL
Intervention: MP plus Static Back Endurance Exercise Group (MPSBEEG)
Number of subjects: 84
Study 24624241 — intervention group
Group type: EXPERIMENTAL
Intervention: MP plus Dynamic Endurance Exercise Group (MPDBEEG)
Number of subjects: 84
Study 24624241 — intervention group
Group type: EXPERIMENTAL
Intervention: MP, MPSBEEG, MPDBEEG
Number of subjects: 84
Study 24624241 — intervention group
Group type: EXPERIMENTAL
Intervention: MPDBEEG
Number of subjects: 84
Study 23276436 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (100 μg of selenium as selenium-yeast)
Number of subjects: 166
Study 23276436 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo-yeast tablet)
Number of subjects: 166
Study 20678675 — intervention group
Group type: EXPERIMENTAL
Intervention: Barnidipine 10 mg plus losartan 50 mg
Number of subjects: 93
Study 20678675 — intervention group
Group type: COMPARATOR
Intervention: Losartan 100 mg monotherapy
Number of subjects: 93
Study 18247017 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib in combination with gemcitabine
Number of subjects: 0
Study 18247017 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 15781902 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 131
Study 15781902 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic walking
Number of subjects: 131
Study 15781902 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined resistance and aerobic walking
Number of subjects: 131
Study 15781902 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise control group
Number of subjects: 131
Study 12472549 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily dithranol in Lassar's paste
Number of subjects: 61
Study 12472549 — intervention group
Group type: COMPARATOR
Intervention: Once-daily dithranol in Lassar's paste
Number of subjects: 61
Study 9579002 — intervention group
Group type: EXPERIMENTAL
Intervention: IHDP intervention
Number of subjects: 0
Study 7638914 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot water systems with temperatures above 60 degrees C
Number of subjects: 75
Study 7638914 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold tap water and returning water temperatures
Number of subjects: 75
Study 7638914 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of Legionella pneumophila
Number of subjects: 75
Study 7638914 — intervention group
Group type: EXPERIMENTAL
Intervention: Serogroups of Legionella pneumophila
Number of subjects: 75
Study 7638914 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimization of hot tap water systems
Number of subjects: 75
Study 7638914 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic consideration for primary atypical pneumonia
Number of subjects: 75
Study 2930095 — intervention group
Group type: COMPARATOR
Intervention: Control (protocol for smoking management and a lecture on the consequences and management of smoking)
Number of subjects: 1420
Study 2930095 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum available to patients
Number of subjects: 1420
Study 2930095 — intervention group
Group type: EXPERIMENTAL
Intervention: Stickers attached to smokers' charts (reminder)
Number of subjects: 1420
Study 2930095 — intervention group
Group type: EXPERIMENTAL
Intervention: Both gum and reminders
Number of subjects: 1420
Study 345986 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass with membrane and bubble oxygenators
Number of subjects: 40
Study 345986 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro aggregation tests with protamine sulfate and hemoglobin solutions
Number of subjects: 40
Study 345986 — intervention group
Group type: EXPERIMENTAL
Intervention: 14C‐serotonin tests
Number of subjects: 40
Study 345986 — intervention group
Group type: EXPERIMENTAL
Intervention: Electron micrographs of platelets
Number of subjects: 40
Study 345986 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of blood loss, blood transfused, and plasma hemoglobin levels
Number of subjects: 40
Study 30107477 — intervention group
Group type: EXPERIMENTAL
Intervention: Smooth surface tissue expanders (STE)
Number of subjects: 112
Study 31189520 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide (flexible dose adjustments to 3, 7, or 14 mg once daily)
Number of subjects: 504
Study 31189520 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 100 mg once daily
Number of subjects: 504
Study 31189520 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Number of subjects: 504
Study 31189520 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 504
Study 27859100 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief OurRelationship.com (Brief-OR) program with staff support
Number of subjects: 0
Study 27859100 — intervention group
Group type: COMPARATOR
Intervention: Brief OurRelationship.com (Brief-OR) program without staff support
Number of subjects: 0
Study 26152818 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide
Number of subjects: 0
Study 26152818 — intervention group
Group type: COMPARATOR
Intervention: Fosphenytoin
Number of subjects: 0
Study 23571145 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal amplitude modulated signal (TAMS)
Number of subjects: 10
Study 23571145 — intervention group
Group type: COMPARATOR
Intervention: Conventional stimuli
Number of subjects: 10
Study 22091750 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid on feeding options in advanced dementia
Number of subjects: 256
Study 22091750 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 256
Study 19486178 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 85 mg/naproxen sodium 500 mg
Number of subjects: 283
Study 19486178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study 16866586 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nicotine patch
Number of subjects: 70
Study 16866586 — intervention group
Group type: COMPARATOR
Intervention: Placebo nicotine patch
Number of subjects: 70
Study 12730150 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP treatment
Number of subjects: 18
Study 12730150 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched infants)
Number of subjects: 18
Study 11007576 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO (2 g/kg body wt carbohydrate in a 10% solution)
Number of subjects: 7
Study 11007576 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex (75 min of semirecumbent cycling exercise at 75% of peak O(2) consumption)
Number of subjects: 7
Study 11007576 — intervention group
Group type: EXPERIMENTAL
Intervention: ExCHO (Ex followed by ingestion of carbohydrate solution)
Number of subjects: 7
Study 9084462 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (0.2 mg/kg three times daily during 14 days)
Number of subjects: 39
Study 9084462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 9084462 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 39
Study 8452061 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayre spatula used second
Number of subjects: 665
Study 8452061 — intervention group
Group type: COMPARATOR
Intervention: Ayre spatula used first
Number of subjects: 665
Study 8452061 — intervention group
Group type: EXPERIMENTAL
Intervention: Curved brush used second
Number of subjects: 665
Study 8452061 — intervention group
Group type: COMPARATOR
Intervention: Curved brush used first
Number of subjects: 665
Study 8452061 — intervention group
Group type: EXPERIMENTAL
Intervention: Curved brush
Number of subjects: 665
Study 8452061 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatula
Number of subjects: 665
Study 3961091 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual short-term psychotherapy in combination with medical treatment
Number of subjects: 103
Study 3961091 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment only
Number of subjects: 103
Study 31777210 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive simulation training every 6 weeks for 1 year
Number of subjects: 12
Study 31777210 — intervention group
Group type: COMPARATOR
Intervention: Control group with 3 simulations at 3 time points (starting point, 6 months, and 1 year)
Number of subjects: 12
Study 30168413 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (32-35 °C)
Number of subjects: 387
Study 30168413 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 387
Study 27777054 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous kyphoplasty (PKP)
Number of subjects: 139
Study 27777054 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adjacent vertebral compression fracture)
Number of subjects: 139
Study 25234311 — intervention group
Group type: EXPERIMENTAL
Intervention: ADPKD patients with eGFR >60 ml·min(‐1)·1.73 m(‐2)
Number of subjects: 110
Study 25234311 — intervention group
Group type: EXPERIMENTAL
Intervention: ADPKD patients
Number of subjects: 110
Study 25234311 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 110
Study 22558687 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Sensitive Pro‐Relief toothpaste containing 8.0% arginine, 1450 ppm MFP and calcium carbonate
Number of subjects: 120
Study 22558687 — intervention group
Group type: COMPARATOR
Intervention: Colgate Cavity Protection toothpaste containing 1450 ppm MFP and calcium carbonate
Number of subjects: 120
Study 22558687 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Test and Control groups
Number of subjects: 120
Study 20883534 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold, pulsatile machine perfusion (MP)
Number of subjects: 90
Study 20883534 — intervention group
Group type: COMPARATOR
Intervention: Simple cold storage (CS)
Number of subjects: 90
Study 19011772 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino-acid infusion (4 kJ x kg(‐1) x h(‐1))
Number of subjects: 24
Study 19011772 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 24